Cyclic guanosine monophosphate (cGMP) is an important intracellular second messenger that mediates multiple tissue and cellular responses. The cGMP pathway is a key player in cardiac pathophysiology, and its modulation by drugs such as phosphodiesterase inhibitors and guanylate cyclase activators may represent a promising therapeutic approach for acute myocardial infarction, cardiac hypertrophy, heart failure, and doxorubicin cardiotoxicity in patients. Furthermore, PDE-5 inhibitors may prove to be novel therapeutic agents for improving doxorubicin chemosensitivity while also providing cardiac benefits.

Cyclic guanosine monophosphate (cGMP) is a crucial intracellular second messenger that regulates fundamental myocardial physiological processes, from acute contraction/relaxation to chronic gene expression, cell growth, and apoptosis.

[size= 12.0pt; mso-bidi-font-size: 10.5pt; line-height: 115%; font-family: 'Calibri Light','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-IN; mso-bidi-language: AR-SA] <!--[endif]-->[/size]

For more information visit our site: Genericpharmamall